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Abstract 
Background and aim: To construct proper and externally validate cut-off points for log odds of 
positive lymph nodes scheme (LODDS) staging scheme in colorectal cancer (CRC).  
Patients and methods: The X-tile approach was used to find the cut-off points for the novel 
LODDS staging scheme in 240,898 patients from the Surveillance, Epidemiology and End Results 
(SEER) database and externally validated in 1,878 from the international multicenter cohort. 
Kaplan-Meier plot and multivariate Cox proportional hazard models were performed to investigate 
the role of the novel LODDS classification.  
Results: The prognostic cut-off values were determined as -2.18, and -0.23 (P< 0.001). Patients had 
5-year cancer-specific survival rates of 83.8%, 57.4% and 24.4% with increasing LODDS (P< 0.001) in 
the SEER database. Five-year overall survival rates were 77.2%, 55.0% and 26.7% with increasing 
LODDS (P< 0.001) in the external international multicenter cohort. Multivariate survival analysis 
identified both the LODDS classification, the patient’s age, the T category, the M status, and the 
tumor grade as independent prognostic factors in both two independent databases. The analyses of 
the subgroup of patients stratified by tumor location (colon or rectum), number of retrieved lymph 
node (< 12 or ≥ 12), TNM stage III, lymph node-negative also confirmed the LODDS as independent 
prognostic factors (P< 0.001) in both two independent databases. 
Conclusions: The novel LODDS classification was an independent prognostic factor for patients 
with CRCs and should be calculated for additional risk group stratification with pN scheme. 
Key words: Colorectal cancer, cause-specific survival, overall survival, log odds of positive lymph nodes, 
multicenter, SEER. 
Introduction 
The presence of lymph node metastases (LNM) 
and the number of lymph node metastasis, also called 
the number of positive lymph node (pN), are robust 
risk factors in patients with colorectal cancers (CRCs) 
[1], which may determine subsequent adjuvant 








the number of involved LNM, CRCs could be 
classified as pN0, pN1 (1-3 tumor invaded LNM), and 
pN2 (4 and more tumor invaded LNM) cancers [4].  
Adequate lymph node histopathological 
assessment is of significant impact on accurate pN 
staging but the minimum of recommendations in the 
literature ranged significantly [5-7]. In order to avoid 
stage migration effect, adequate evaluation of the 
lymph node status is of great importance and, to date, 
the widely accepted minimum number of retrieved 
lymph nodes is 12 [8-10]. However, it was surprising 
that the reported numbers of retrieved lymph nodes 
(rN) in CRCs varied widely in published literatures, 
median ranging from 6 to 13 [11, 12], though precise 
recommendations and guidelines are available.  
Considering inadequate examination of lymph 
nodes in nearly half of CRC patients, it is urgent to 
recommend new measures of lymph node status with 
combination of rN. To the best of our knowledge, two 
measures, namely lymph node ratio (LNR) [13], log 
odds of positive lymph nodes (LODDS) [14] have 
been proposed. Multiple studies have shown 
superiority of LNR to pN in accurately predicting 
patient’s survival [13, 15]. Although LNR seems to be 
a superior predictor of survival in Stage III colorectal 
cancer [7, 15-18], the results remained controversial, 
particularly in CRC with no LNM and inadequate rN. 
In node-negative CRCs accounting for more than half 
of CRCs [19], LNR0, same to pN0 classification, does 
not provide any more additional prognostic 
evaluation than pN0. In this situation, patients with 
no LNM may be at high risk of understaging with lack 
of adequate of rN and incorrect choice of 
postoperative adjuvant treatments after surgery may 
be made. 
LODDS has been recently proposed as a new 
prognostic index in CRCs [14, 20-23], showing 
powerful ability to classify patients into different 
groups with homogeneous survival, regardless of 
lymph node status and count. However, different 
methods were used in different studies to determine 
their cut-off LODDS values. Three studies used 
statistical methods to calculate cut-off values in 
limited numbers of patients [14, 21, 23]. Two studies 
even used arbitrary classification for investigation [20, 
22]. Though Song’s study [23] used the statistical 
method to calculate cut-off values in relative large 
number of CRC patients, its cut-off values were not 
validated in other populations. 
In the present study, we aimed to find optimal 
categorization of LODDS values using X-tile approach 
in a large population-based database involving 
240,898 CRCs and validate our determined LODDS 
cut-off values in the international multicenter cohort, 
providing a more precise lymph node staging scheme 
for patients with CRCs.  
Method 
Surveillance, Epidemiology and End Results 
Database 
Patients with CRCs from Surveillance, 
Epidemiology, and End Results (SEER) database were 
created and collected through query to the latest 
version of the SEER 18 Regs Research data 
(1973-2014), released in April 2017 with the SEER*Stat 
8.3.5 software. The inclusion criteria for selected 
patients were as follows: 1) Patients aged 18 years old 
or more diagnosed between 1988 and 2010; 2) Patients 
with CRCs diagnosed as the only primary cancers 
without multiple primary cancers elsewhere; 3) 
Patients with cancers diagnosed microscopically, in 
whom surgery for primary cancers and regional 
lymph node resection had been performed with 
pathological examination of at least one lymph node; 
4) International Classification of Diseases for 
Oncology third edition (ICD-O-3) codes were used as 
8010-8231 and 8255-8576 for CRCs; 5) Patients with 
active follow-up for at least 2 months. Patients were 
excluded if they received radiotherapy before surgery 
or CRC was not the only one primary carcinoma or 
the number of retrieved lymph nodes and positive 
lymph nodes were missing.  
For SEER database, cancer-specific survival 
(CSS) was defined as death due to CRC and OS was 
defined as death regardless of any causes. The 
primary outcome was CSS with OS and CSS 
considering competing death due to non-CRC death 
as the secondly outcome. Survival time was defined as 
the time from diagnosis to the date of death or last 
contact or Nov 2016. 
Since SEER database is public-use data, no 
institutional review was required, and we have been 
allowed to access SEER database for only research 
using the private SEER ID (zhangqw). 
International multicenter cohort 
An independent international multicenter cohort 
from three medical centers was used as validation 
group using the same inclusion and exclusion criteria. 
Patients who underwent colectomy for 
histopathological confirmed CRC from February 2004 
to March 2017 in Renji Hospital of of Shanghai Jiao 
Tong University, Shanghai Ninth People's Hospital of 
Shanghai Jiao Tong University and from January 2004 
to April 2017 in Catholic University of Rome were 
selected. The follow-up time in the two Chinese 
hospitals was every 6 months until death or study 
ended (30th March 2018), except for those lost to 
follow-up. For patients in the Catholic University of 




Rome, the patients were followed up until death or 
study end (30th April 2018) except for those lost to 
follow-up according to the European Society of 
Medical Oncology guidelines [24]. 
This study was approved by the Institutional 
Review Board in the all participating hospital. 
Definitions of node staging scheme 
Two values, namely pN and the number of 
negative lymph node (nN), were needed to calculate 
LODDS values. The pN value indicates the number of 
positive lymph node. rN value is defined as the 
number of retrieved lymph nodes for histological 
examination of lymph node metastasis status. The nN 
value is the absolute number of negative lymph node, 
which is calculated by subtracting pN value from the 
total number of rN value. The LODDS value is 
defined as loge ([pN + 0.5]/ [nN + 0.5]). As a 
continuous variable, LODDS values are then classified 
as a novel five-subgroup LODDS classification using 
proper cut-off points using the X-tile [25]. 
Statistical analysis 
For descriptive statistics, the absolute number 
with proportion for categorical variable, mean and 
standard deviation for continuous variable with 
Gaussian distribution and median and interquartile 
range (IQR) for continuous variable with 
non-normally distribution were used respectively. 
The chi-square test for categorical variable, Student's 
t-test for continuous variable with Gaussian 
distribution and the nonparametric Kruskal-Wallis 
rank sum test for continuous variable with 
non-normally distributed data were used for 
comparisons among different patient groups 
respectively. The above descriptive statistics and 
exploratory comparisons were done using CBCgrps 
package [26]. 
For survival analysis, Kaplan-Meier method was 
performed to calculate and show survival rates in 
different patient groups with log-rank test used for 
statistical comparisons. Meanwhile, multivariate Cox 
regression models with variable selection procedures 
were used to explore potential risk factors associated 
with patient’s survival. Besides, cumulative 
probability of CRC-specific death and multivariate 
regression modeling of subdistribution functions in 
competing risks were also performed for sensitivity 
analysis for our findings using cmprsk package [27]. 
Five-year survival rate and hazard ratios (HRs) were 
calculated with 95% confidence intervals (CIs). 
To determined optimal categorization of LODDS 
values, X-tile technique was used to define the 
optimal cut-off points by the log-rank test [25]. Firstly, 
X-tile technique would divide the population into 
low-, medium- and high-level LODDS value by every 
possible cut-off. Then, survival between all possible 
divisions according to LODDS values were tested by 
the log-rank test. Finally, the optimal LODDS cut-off 
would be selected by selecting the highestχ2 value. 
Statistical analyses and plotting graphics were 
conducted using R software package (version R-3.4.3, 
the R Foundation for statistical computing). All 
statistical comparisons were considered significant 
with P< 0.05. 
Results 
Clinical characteristics of patients from SEER 
database and the international multicenter 
cohort 
With defined inclusion and exclusion criteria 
(Supplementary Figure 1), a total of 240,898 patients 
with CRCs were finally identified from the SEER 
database. As shown in the Table 1, the median 
number (IQR) of retrieved lymph nodes was 12 (7, 18) 
for the total patient group. The median number (IQR) 
of continuous LODDS value for the total patient 
group was -2.51 (-3.3, -1.21) and the follow-up time 
was 65 (26, 116) months.  
With the same inclusion and exclusion criteria as 
SEER database, we identified 1,878 patients from the 
international multicenter cohort. In the international 
multicenter cohort, the median number (IQR) of 
retrieved lymph nodes was 10 (5, 14) for the total 
patient group. The median number (IQR) of 
continuous LODDS value for the total patient group 
was -2.51 (-3.3, -1.21) and the follow-up time was 48 
(21, 75) months. 
The remaining clinicalpathological 
characteristics for SEER database and the 
international multicenter cohort could be seen in the 
Table 1. 
 
Table 1. Characteristics of patients with colorectal cancer in 
Surveillance, Epidemiology, and End Results database (N= 240898) 
and the international multicenter cohort (N= 1878). 
  No. of patients (Percent) 
  SEER database multicenter 
cohort 
Race White  195333 (81.30%) NA 
 Black 25280 (10.52%) NA 
 Others 19654 (8.18%) NA 
Sex Female 125827 (52.23%) 811 (43.23%) 
 Male 115071 (47.77%) 1065 (56.77%) 
Age (year) Median (IQR) 69 (59, 78) 68 (59, 76) 
 < 60 64750 (27%) 489 (26.26%) 
 ≥ 60 176148 (73%) 1373 (73.74%) 
Tumor size (cm) Median (IQR) 4.40 (3.00, 6.00) 4.50 (3.50, 6.00) 
 ≤ 2 24020 (11.18%) 116 (6.24%) 
 ≤ 3 34309 (15.96%) 269 (14.47%) 




 ≤ 5 85233 (39.65%) 823 (44.27%) 
 > 5 71390 (33.21%) 651 (35.02%) 
Tumor site Proximal colon 119078 (50.13%) 604 (32.46%) 
 Distal colon 79834 (33.61%) 779 (41.86%) 
 Rectum 38642 (16.27%) 478 (25.69%) 
Histology Adenocarcinoma 211146 (87.65%) 1688 (89.83%) 
 Mucinous 
adenocarcinoma 
25809 (10.71%) 186 (9.91%) 
 Signet ring cell 
carcinoma 
2371 (0.65%) 4 (0.21%) 
 Others 1572 (0.98%) NA 
Grade Well/Moderately 
differentiated 
182915(79.67%) 1327 (71.89%) 
 Poorly or 
undifferentiated 
46663 (20.33%) 519 (28.11%) 
7th T stage T1 31113 (14.21%) 113 (6.09%) 
 T2 35099 (16.03%) 219 (11.81%) 
 T3 124422 (56.82%) 1246 (67.17%) 
 T4 28372 (12.94%) 277 (14.93%) 
7th M stage M0 203532 (84.83%) 1739 (92.60%) 
 M1 36400 (15.17%) 137 (7.29%) 
Total no. of nodes 
retrieved 
Median (IQR) 12 (7, 18) 10 (5, 14) 
No. of negative 
nodes (nN) 
Median (IQR) 10 (6, 16) 8 (4, 13) 
No. of positive 
nodes (pN) 
Median (IQR) 0 (0, 2) 0 (0, 2) 
7th N stage (7th pN) N0 141131 (58.59%) 1131 (60.22%) 
 N1 58625 (24.33%) 496 (26.41%) 
 N2 41142 (17.07%) 251 (13.37%) 
LODDS Median (IQR) -2.51 (-3.3, -1.21) -2.20 (-3.13, -1.10) 
LODDS 
classification 
≤ -2.18 141403(58.70%) 1031 (54.90%) 
 -2.18 – -0.23 69821 (28.98%) 616 (32.80%) 
 > -0.23 29674 (12.32%) 231 (12.30%) 
Follow-up 
(months) 
Median (IQR) 65 (26, 116) 48 (21, 75) 
LODDS: log odds of positive lymph nodes; NA: not available; IQR: interquartile 
range.  
 
Clinical characteristics and survival rate 
among different novel LODDS group: 
derivation and validation 
The X-tile analysis finally identified optimal 
thresholds of LODDS. The novel LODDS group 
classified by the cut-off values of -2.18, -0.23 showed 
the highestχ2 value for the CSS. Therefore, a novel 
LODDS classification subgroup was determined in 
this study using the above LODDS cut-off points: 
LODDS1 (-2.18 or less), LODDS2 (more than -2.18 to 
-0.23) and LODDS3 (more than -0.23).  
We explored association between LODDS 
classification subgroup and clinical and 
histopathological characteristics. Results (Table 2) 
showed positive correlation of LODDS classification 
with T stage (P< 0.001), N stage (P< 0.001), M stage 
(P< 0.001), pN (P< 0.001) and negative correlation 
with nN (P< 0.001), which supported rationality of the 
novel LODDS group. Of 240,898 patients analyzed, 
141,403 (58.70%) patients were classified as LODDS1 
group with 5-year CSS of 83.8% (83.6%–84.0%), 69,821 
(28.98%) patients were classified as LODDS2 group 
with 5-year CSS of 57.4% (57.0%- 57.8%), 29,674 
(12.32%) patients were classified as LODDS3 group 
with 5-year CSS of 24.4% (23.9%–24.9%). Therefore, 
increased LODDS classification had significant 
positive association with poor CSS (Figure 1A, P< 
0.001). Besides, increased LODDS classification had 
significant positive association with poor OS (Figure 
1B, P< 0.001) and higher cumulative probability of 
cancer-specific death (Figure 1C, P< 0.001). 
 
 
Table 2. Comparison of log odds of positive lymph nodes distribution with histopathological parameters in the SEER database and 
international database. 
 SEER database  International multicenter database 
 Total  ≤ -2.18  -2.18 – -0.23  > -0.23  P  Total  ≤ -2.18  -2.18 – -0.23  > -0.23  P 
 N (%)  N (%)  N (%)  N (%)   N (%)  N (%)  N (%)  N (%)  
T 
stage 
        < 
0.001 
         < 
0.001 
 T1 31113(14.21%)  24120(17.72%)  6602(10.75%)  391(1.82%)    113(6.09%)  94(9.19%)  19(3.13%)  0(0)   
 T2 35099(16.03%)  27440(20.16%)  6720(10.94%)  939(4.37%)    219(11.81%)  164(16.03%)  48(7.91%)  7(3.11%)   
 T3 124422(56.82%)  71960(52.88%)  38341(62.43%)  14121(65.76%)    1246(67.17%)  651(63.64%)  425(70.02%)  170(75.56%)   
 T4 28346(12.94%)  12568(9.24%)  9756(15.88%)  6022(28.04%)    277(14.93%)  114(11.14%)  115(18.95%)  48(21.33%)   
N 
stage 
        < 
0.001 
         < 
0.001 
 N0 141131(58.59%)  126873(89.72%)  14258(20.42%)  0(0)    1131(60.22%)  974(94.47%)  157(25.49%)  0(0)   
 N1 58625(24.34%)  14357(10.15%)  38442(55.06%)  5826(19.63%)    496(26.41%)  57(5.53%)  369(59.90%)  70(30.30%)   
N2 41142(17.08%)  173(0.12%)  17121(24.52%)  23848(80.37%)    251(13.37%)  0(0)  90(14.61%)  161(69.70%)   
rN 12(7,18)  14(9,20)  11(5,16)  10(6,15)  < 
0.001 
 10(5,14)  11(7,15)  8(3,13)  7(4,11)  < 
0.001 
pN 0(0,2)  0(0,0)  2(1,3)  7(4,10)  < 
0.001 
 0(0,2)  0(0,0)  1(0,3)  4(3,7)  < 
0.001 
nN 10(6,16)  14(9,20)  8(4,13)  3(1,5)  < 
0.001 




        < 
0.001 
         < 
0.001 
 M0 203532(84.83%)  132809(94.26%)  54777(78.81%)  15946(53.99%)    1739(92.70%)  1002(97.38%)  546(88.64%)  191(82.68%)   
 M1 36400(15.17%)  8086(5.74%)  14727(21.19%)  13587(46.01%)    137(7.30%)  27(2.62%)  70(11.36%)  40(17.32%)   
SEER: Surveillance, Epidemiology, and End Results; rN: number of retrieved lymph nodes; pN: number of positive lymph node; nN: number of negative lymph node. 
 





Figure 1. Cancer-specific survival (A), overall survival (B) and cumulative probability of Cancer-specific death (C) of 240, 898 patients in the Surveillance, 
Epidemiology, and End Results database and overall survival (D) of 1, 878 patients in the international multicenter cohort stratified according to the log odds of 
positive lymph nodes. 
 
We next validated the novel LODDS 
classification in the international multicenter cohort. 
As is shown in the Table 2, LODDS classification also 
showed positive correlation with T stage (P< 0.001), N 
stage (P< 0.001), M stage (P< 0.001), pN (P< 0.001) and 
negative correlation with nN (P< 0.001) in the 
international multicenter cohort, which was 
consistent with findings in SEER database. Of 1,878 
patients analyzed, 1,031 (54.90%) patients were 
classified as LODDS1 group with 5-year OS of 77.2% 
(74.4%–80.1%), 616 (32.80%) patients were classified 
as LODDS2 group with 5-year OS of 59.2% (54.3%–
64.5%), 231 (12.30%) patients were classified as 
LODDS3 group with 5-year OS of 45.9% (39.0%–
54.2%). Therefore, increased LODDS classification 
had significant positive association with poor OS 
(Figure 1D, P< 0.001).  
We further explored whether the established 
LODDS classification could classify patients into 
groups with homogeneous survival. As is shown in 
the Table 3, there were no patients with N0 disease 
had an LODDS larger than -0.23. However, within the 
N0 subgroups, one can see a difference in 5-year OS 
between patients with LODDS1 (72.0% in the SEER 
database and 77.1% in the international multicenter 
cohort) and patients with LODDS2 (64.6% in the SEER 
database and 62.9% in the international multicenter 
cohort). These difference were highlighted in Table 3 
and show the importance of the stratification of 
patients by our novel established LODDS 
classification. 
 
Table 3. Five-Year Survival Rates by LODDS 
 SEER database  International multicenter 
database 












All patients          
CSS 68.9  83.8  57.4  24.4   NA NA NA NA 
OS 58.3  71.0 48.6  20.5  63.2  77.2 55.0  26.7  
N0 patients          
CSS 84.7  85.3  79.6  NA  NA NA NA NA 
OS 71.2  72.0  64.6  NA  74.8  77.1 62.9  NA 
N1 patients          
CSS 57.2  70.9  55.6  33.7   NA NA NA NA 
OS 49.0 62.4  47.3  27.3   51.5  78.2  51.6  32.9  
N2 patients          
CSS 31.2  60.7  43.4  22.1   NA NA NA NA 
OS 27.1  54.2  38.3  18.9   32.6  NA 52.7  23.4  




Multivariate Cox analysis: role of novel 
LODDS classification in patients’ survival 
As is shown in the Figure 2, multivariate Cox 
model, which included LODDS classification and all 
potential risk factors, identified the LODDS 
classification (P< 0.001), sex (P< 0.001), race (P< 0.001), 
age (P< 0.001), tumor location (P< 0.001), grade (P< 
0.001), histology (P< 0.001), T stage (P< 0.001), M stage 
(P< 0.001), and tumor size (P< 0.001) as independent 
prognostic factors. Similar results could be obtained 
using Multivariate Cox analysis with OS as outcome 
(Supplementary Figure 2) and multivariate regression 
modeling of subdistribution functions in competing 
risks (Supplementary Table 1). As is shown in the 
Figure 3, it was validated in the international 
multicenter cohort that LODDS classification, and all 
prognostic factors were identified as independent 
prognostic factors. 
We next analyzed whether LODDS classification 
was also an independent risk factors in different 
subgroups using multivariate Cox regression in the 
SEER database and the international multicenter 
database. As is shown in Figure 4A, LODDS 
classification was identified as an independent risk 
factor in CRC with number of examined lymph nodes 
>=12, number of examined lymph nodes <12, 7th TNM 
stage III, colon cancer, rectal cancer or cancer without 
lymph node involvement. Similar results could be 
obtained in the international multicenter cohort 
(Figure 4B). 
Studies have shown that pN category did not 
show powerful prognostic impact in patients with 
TNM stage III colorectal cancers [15, 28].  
 
 
Figure 2. Forest plot showing results of multivariate Cox regression model for exploring potential risk factors with inclusion of covariate log odds of positive lymph 
nodes for cancer-specific survival in 240, 898 patients of the Surveillance, Epidemiology, and End Results database. 





Figure 3. Forest plot showing results of multivariate Cox regression model for exploring potential risk factors for overall survival in 1,878 patients of the 
international multicenter cohort. 
 
Figure 4. Forest plot showing subgroup analyses results of multivariate Cox regression model stratified by different characteristics in the Surveillance, Epidemiology, 
and End Results database and international multicenter database. 
 





In this study, we presented a population-based 
analysis of 240,898 patients in SEER database and 
international multicenter analysis of 1,878 patients in 
three medical centers. Our analyses showed that 
LODDS was a powerful prognostic factor for CSS or 
OS in patients with CRCs in both SEER database and 
international multicenter cohort. We identified cut-off 
values -2.18 and -0.23 for LODDS classification. We 
demonstrated that the novel LODDS classification 
had significant prognostic impact on CSS or OS in 
SEER database and the present study was the first 
study to validate prognostic impact of the novel 
LODDS classification on survival in an independent 
cohort from 3 medical centers. 
Although pN classification of AJCC TNM 
classification is the most commonly used staging 
system for CRCs, it only relies on the number of 
positive lymph node without the number of retrieved 
lymph node or the number of negative lymph node, 
which are also associated with survival [7, 13, 29]. 
Therefore, only when the rN is 12 or more, pN 
category could be regarded as accurate staging [30, 
31]. However, case with less than 12 rN are not 
unusual in clinical practice, which lead to 
development of new lymph node staging schemes 
incorporating all the two lymph node information in 
one single variable. Among the schemes, LNR and 
LODDS are most promising classifications [13, 14]. 
During the last one decade, multiple studies have 
poured out that LNR was comparable and even 
superior to that of well-established prognostic factors, 
such as TNM classification, in CRCs [13, 15]. 
Unfortunately, LNR has some drawbacks: it do not 
provide any meaningful information in node-negative 
CRCs; it do not predict survival well in patients 
without adequate rN [13]; it also cannot discriminate 
survival difference among patients with all lymph 
nodes invaded. The other scheme LODDS could solve 
the above mentioned drawbacks of LNR. 
To date, several groups have reported the 
prognostic impact of LODDS in colorectal cancer 
(Supplementary Table 2) [14, 20-23]. Of them, 3 
studies used statistical methods to calculate cut-off 
values of LODDS for optimal discrimination. The first 
study [23] used running log-rank statistics to calculate 
using OS as primary outcome for CRCs in Chinese 
single-center cohort of limited number of 1297 
patients. Our previous study [14] used log-rank test 
for optimization also using OS in only colon cancers 
in single-center cohort of limited number of 258 
patients. The last study used regression trees 
technique for classification also using OS in CRCs in 
Chinese single-center cohort of limited number of 192 
patients [21]. The other 2 studies [20, 22] even used 
arbitrary cut-off values for optimization. None of 
LODDS cut-off values in these studies were validated 
in another independent cohort. Therefore, there is still 
lack of proper and accurate LODDS classification. 
This study was the first study to use the largest 
number of CRCs for optimization of LODDS using 
minimal P approach on X-tile software [25] with 
additionally external validation of determined 
LODDS cut-off values in an independent international 
cohort. Different from the above mentioned studies, 
our study used CSS as primary outcome instead of 
OS, since prognostic risk factors for CSS could more 
truly reflect death due to CRCs. Besides, we also 
tested our cut-off values for OS and CSS under 
competing risk model with positive results. 
One of reason why LODDS is superior to pN or 
LNR is its prognostic classification of node-negative 
CRCs patients (pN0 or LNR0). In our study, we found 
our determined LODDS cut-off values could classify 
patients with node-negative CRCs into two 
homogeneous groups with significant prognostic 
difference, which were consistent with results in other 
studies [14, 22]. In the future, we will evaluate the 
three lymph node schemes in predicting survival in 
patients with CRCs to explore whether LODDS is 
superior to pN or LNR and potential mechanism 
deeply. Besides, we will try to build a new TNM stage 
system using our determined LODDS classification 
for survival optimization of CRCs patients.  
Limitation should be discussed in this study. 
Firstly, it was a retrospective exploratory study based 
on SEER database and an independent multicenter 
cohort, clinical and histological characteristics may 
differ among different registers or hospitals. 
However, it was actually representative of clinical 
practice in the real world. Secondly, the follow-up 
time and number of patients in the independent 
multicenter cohort were shorter than those in SEER 
database. It would be better to externally validate our 
findings in another large multicenter-based cohort or 
population-based register with longer follow-up time. 
Thirdly, the study includes patients between 1988 and 
2010 when the standard of care for these patients has 
improved and thus the prognosis has changed. 
However, we did a subgroup analysis stratified by the 
time of diagnosis, and results showed patients with 
LODDS2 or LODDS3 still had poorer prognosis than 
patients with LODDS1, which indicated that time of 
diagnosis had limited impact on LODDS classification 
for prognosis of CRCs. However, our study was 
different from other studies about LODDS 
classification in CRCs of which only three [14, 21, 23] 
used the statistical method to find the optimal cut-off 
values for LODDS and none tested whether their 




LODDS classification still had significant impact on 
prognosis in the other independent validation 
datasets. We used the largest number of CRCs for 
optimization of LODDS using minimal P approach on 
X-tile software. We also used the international 
multicenter cohort to test whether our established 
LODDS classification still had significant impact on 
prognosis in the other independent validation 
datasets with positive results. In the future, we would 
also develop a novel prediction model based on our 
established LODDS classification. 
In summary, the present study involved the 
largest number of CRCs to identify the optimal 
thresholds of LODDS and was the first study to 
evaluate the determined cut-off values of LODDS in 
an independent multicenter cohort. The LODDS 
classification, with cut-off values -2.18, and -0.23, was 
an independent prognostic factor in patients with 
CRCs regardless of tumor location, number of 
retrieved lymph node, stage III and node-negative 
cancers. LODDS could improve the prognostic power 
of current staging systems and should be documented 
additionally for cancer staging of CRCs. 
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